Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 17;384(24):2352-2354.
doi: 10.1056/NEJMc2103740. Epub 2021 Apr 7.

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

Xiaoying Shen  1 , Haili Tang  1 , Rolando Pajon  2 , Gale Smith  3 , Gregory M Glenn  3 , Wei Shi  4 , Bette Korber  5 , David C Montefiori  6
Affiliations

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

Xiaoying Shen et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Neutralization of B.1.429 and B.1.351 Pseudoviruses in Serum Samples Obtained from Convalescent Persons and Vaccine Recipients.
Convalescent serum samples were obtained from infected persons 1 to 8 weeks after resolution of coronavirus disease 2019 infection or 2 to 10 weeks after the most recent positive SARS-CoV-2 test. Serum samples were obtained from recipients of the Moderna vaccine on day 57 (28 days after the second vaccine dose), and Novavax serum samples were obtained from vaccine recipients on day 35 (14 days after the second vaccine dose). Results are shown as the difference in neutralization titers of matched samples (Panels A and B) and the difference in titers relative to the D614G variant (the ratio of titers against the variant indicated) for each sample set (Panel C). Lower values indicate stronger cross-neutralization of the variant virus. Dashed thin lines in Panels A and B represent individual samples, and thick black lines represent the geometric means of each sample group, as indicated at the right. Thick black bars in Panel C represent the geometric mean titer differences for the sample sets, which are also labeled above each set. Circles in Panel C represent the differences in titers relative to D614G for individual samples. P values for the comparison of the reciprocal neutralization titers at 50% inhibitory dilution (ID50) and 80% inhibitory dilution (ID80) are pairwise comparisons of the data shown in Panels A and B, calculated with the use of the Wilcoxon signed-rank test. P values less than 0.001 correlate to Q (adjusted P) values less than 0.0019 (see Table S2 in Supplementary Appendix 2). Differences in the neutralization titers among the three sample sets shown in Panel C were not significant (P>0.05 by the Wilcoxon rank-sum test).
See this image and copyright information in PMC

References

    1. Zhang W, Davis BD, Chen SS, Martinez JMS, Plummer JT, Vail E. Emergence of a novel SARS-CoV-2 strain in southern California, USA. January 20, 2021. (https://www.medrxiv.org/content/10.1101/2021.01.18.21249786v1). preprint. - PMC - PubMed
    1. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020;383:2427-2438. - PMC - PubMed
    1. Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med 2020;383:2320-2332. - PMC - PubMed
    1. Shen X, Tang H, McDanal C, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe 2021. March 05 (Epub ahead of print). - PMC - PubMed
    1. Wu K, Werner AP, Koch M, et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N Engl J Med. DOI: 10.1056/NEJMc2102179. - DOI - PMC - PubMed

Substances